MY162181A - Compositions and methods for modulating hemostasis - Google Patents

Compositions and methods for modulating hemostasis

Info

Publication number
MY162181A
MY162181A MYPI20081594A MYPI20081594A MY162181A MY 162181 A MY162181 A MY 162181A MY PI20081594 A MYPI20081594 A MY PI20081594A MY PI20081594 A MYPI20081594 A MY PI20081594A MY 162181 A MY162181 A MY 162181A
Authority
MY
Malaysia
Prior art keywords
methods
compositions
modulating hemostasis
hemostasis
modulating
Prior art date
Application number
MYPI20081594A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MY162181A publication Critical patent/MY162181A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
MYPI20081594A 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis MY162181A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
MY162181A true MY162181A (en) 2017-05-31

Family

ID=38049397

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20081594A MY162181A (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP2431389A1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR20160029135A (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2629491C (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2496567T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX2008006313A (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP3063170A4 (en) * 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
BR112016014617A2 (pt) * 2014-01-24 2017-09-19 Pfizer Variante do fator xa (fxa) e usos da referida variante
EA202190813A1 (ru) * 2014-05-26 2021-12-31 Академиш Зикенхёйс Лейден Прогемостатические белки для лечения кровотечений
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CN109789181A (zh) 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
JP5833448B2 (ja) * 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用

Also Published As

Publication number Publication date
US9896676B2 (en) 2018-02-20
HK1165444A1 (en) 2012-10-05
US9410137B2 (en) 2016-08-09
NO20082182L (no) 2008-07-30
KR20160029135A (ko) 2016-03-14
JP2009515559A (ja) 2009-04-16
BRPI0618654A8 (pt) 2019-01-15
US20140120155A1 (en) 2014-05-01
AU2006315175B2 (en) 2013-02-07
US20180251745A1 (en) 2018-09-06
JP2018033459A (ja) 2018-03-08
HK1128699A1 (en) 2009-11-06
PL1948690T3 (pl) 2014-11-28
JP5823088B2 (ja) 2015-11-25
SV2008002906A (es) 2008-10-22
CN101356192A (zh) 2009-01-28
WO2007059513A2 (en) 2007-05-24
IL191310A (en) 2015-06-30
RU2011130932A (ru) 2013-01-27
CA2629491C (en) 2019-05-07
JP5957167B2 (ja) 2016-07-27
PT1948690E (pt) 2014-09-08
KR101574042B1 (ko) 2015-12-03
EP1948690A2 (en) 2008-07-30
JP6571735B2 (ja) 2019-09-04
BRPI0618654A2 (pt) 2011-09-06
KR20080078664A (ko) 2008-08-27
KR20140115374A (ko) 2014-09-30
US20090175931A1 (en) 2009-07-09
NO345177B1 (no) 2020-10-26
DK1948690T3 (da) 2014-09-01
BRPI0618654B1 (pt) 2021-10-19
CN101356192B (zh) 2013-09-11
RU2008123398A (ru) 2009-12-27
KR20140005383A (ko) 2014-01-14
EP2423224A1 (en) 2012-02-29
JP6236194B2 (ja) 2017-11-22
US8383386B2 (en) 2013-02-26
JP2016005464A (ja) 2016-01-14
ECSP088452A (es) 2008-07-30
ZA200804026B (en) 2009-10-28
CA2971971A1 (en) 2007-05-24
MX336958B (es) 2016-02-05
WO2007059513A3 (en) 2007-11-29
EP2423224B1 (en) 2015-08-12
AU2006315175A1 (en) 2007-05-24
EP2431390A1 (en) 2012-03-21
EP2431390B1 (en) 2015-08-12
ES2496567T3 (es) 2014-09-19
KR101600158B1 (ko) 2016-03-08
EP1948690A4 (en) 2009-06-17
JP2014073127A (ja) 2014-04-24
CA2629491A1 (en) 2007-05-24
NZ568108A (en) 2011-09-30
GT200800065A (es) 2008-11-03
US20160362673A1 (en) 2016-12-15
ES2549929T3 (es) 2015-11-03
EP1948690B1 (en) 2014-06-11
RU2570547C2 (ru) 2015-12-10
MX337059B (es) 2016-02-09
KR101827569B1 (ko) 2018-02-09
EP2431389A1 (en) 2012-03-21
MX2008006313A (es) 2008-11-06
SI1948690T1 (sl) 2014-09-30
NO20200670A1 (no) 2008-07-30
NO20200671A1 (no) 2008-07-30
CR9956A (es) 2008-08-21

Similar Documents

Publication Publication Date Title
NO20200671A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
AU2016204344A1 (en) Improved methods and compositions for wound healing
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
TN2010000060A1 (en) Proteasome inhibitors
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
ZA200701137B (en) Triazolophthalazines
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
MX2009013170A (es) Particulas de silice y metodos para prepararlas y utilizarlas.
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
TW200738649A (en) Calcilytic compounds
ZA200804082B (en) Compositions and methods for controlling tissue factor signaling specificity
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.
MY162185A (en) Alumina particles and methods of making the same
SG151171A1 (en) Association between an anti-atherothrombotic and an angiotensin- converting enzyme inhibitor
SG126904A1 (en) Articulating anastomotic ring applier
AU2015201137B2 (en) Compositions and method for tissue preservation
WO2007095256A3 (en) Methods of promoting cardiac cell proliferation
AU2006904679A0 (en) Methods of modulating cellular activity and compositions therefor
AU2005905891A0 (en) Methods and compositions for modulating TBF-Beta and collagen